P1.25-09 TARGET: A Phase II Study of 5-year Adjuvant Osimertinib in Completely Resected EGFR-mutated Stage II-IIIB NSCLC

Category Primary study
JournalJournal of thoracic oncology
Year 2023
This article has no abstract
Epistemonikos ID: e834450d12f74be717ef24a91f9e7a8ef4662890
First added on: Apr 29, 2024